te developer and investor in major US cities, primarily New York, LA and Miami. CEO of OSI Pharmaceuticals from 1998 until its $4B acquisition by Astellas Pharmaceuticals in June 2010; joined OSI as a scientist in 1989; presided over transition from $64M market cap to fully integrated biopharmaceutical company with